Drug Pricing
Our work in Drug Pricing
-
White House Signs Bills Banning Gag Clauses, Schaeffer Center Research Pivotal in Discussion
Schaeffer Center report found 23 percent of private claims analyzed involved a copayment that exceeded the insurer’s cost of the drug.
-
Remarks on Medicare Drug Pricing Proposals by Health and Human Services Secretary Alex Azar
On October 26, U.S. Secretary of Health and Human Services Alex Azar visited Brookings to deliver remarks on a top administration priority. After delivering his prepared remarks he sat down for a discussion with Paul Ginsburg.
Categorized in -
Generic Drug Price Hikes And Out-Of-Pocket Spending For Medicare Beneficiaries
The share of generic drugs that at least doubled in price increased fourfold according to the Health Affairs study. But, this share is still a small percentage of the generic market.
Categorized in -
Seminar Series: Chirantan Chatterjee
Chirantan Chatterjee is an associate professor of business policy and economics at the Indian Institute of Management, Ahmedabad. His research focuses on the economics of innovation, applied microeconomics, pharmaceutical economics, and global health.
-
Do Price Spikes on Some Generic Drugs Indicate Problems in the Generics Market?
Despite the overall success of the generic drug market, sudden price hikes are becoming more common according to new Schaeffer Center study
Categorized in -
Trump Might Actually Lower Drug Prices
Dana Goldman and Anupam Jena write in The Washington Post that the Trump administration may succeed in lowering drug prices by fostering competition and innovation, and possibly ending kickbacks in the supply chain.
Categorized in -
Prescription Copay Clawbacks, Explained
A short video on prescription drug overpayments (also known as “clawbacks”). Prescription drug overpayments occur when commercially insured patients’ copayments exceed the total cost of the drug to their insurer or pharmacy benefit manager.
Categorized in -
When We Find a Cure, Price it Like Netflix to Ensure Access
Dana Goldman and his colleagues have shown that such subscription models can improve outcomes and save money at the same time.
Categorized in -
An Economist’s Change of Heart: It’s Time to Regulate the Prescription- Drug Middlemen
Pharmacy-benefit managers find ways to boost their bottom line at the expense of employers and patients, writes Geoffrey Joyce in Market Watch.
Categorized in -
Medicare’s ‘Catastrophic Insurance’ Can Be a Catastrophe for Middle-Income Seniors
Even with Medicare’s catastrophic insurance, middle-income seniors can be on the hook for thousands of dollars for their medications each year, write Erin Trish and Geoffrey Joyce in STAT.
Categorized in